Automated Insulin Delivery for Women with Type 1 Diabetes
Automated Insulin Delivery Versus Usual Insulin Treatment Modality Before and During Pregnancy in Women With Type 1 Diabetes
- Age
- 18 – 45
- Sex
- Female
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 305 (estimated)
- Sponsor
- Rigshospitalet, Denmark · Other
This trial is looking for women aged 18-45 with type 1 diabetes who are planning to become pregnant or are already pregnant. Participants will use an automated insulin delivery system to help manage their diabetes during this time.
You may be able to join if
- I am a woman aged 18-45 years
- I have had type 1 diabetes for at least 12 months
- I am not pregnant and have a negative pregnancy test
- I plan to become pregnant within 52 weeks
- I am pregnant with one living baby confirmed by ultrasound
- I agree to participate in the study during and after my pregnancy
You may not be able to join if
- I cannot understand Danish
- I have severe mental or psychiatric issues
- I have other serious health problems that affect my participation
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityA national multi-center open-label randomized controlled trial that investigates whether the use of the automated insulin delivery system CamAPS FX initiated during pregnancy planning or in early pregnancy improves maternal time in glycemic targets and fetal growth in women with type 1 diabetes compared to usual insulin treatment modality combined with Continuous Glucose Monitoring.
Loading trial locations…
Lene Ringholm Chief physician, PhD, Associate Professor
+45 35458671
CONTACT